Sleisenger and Fordtran's Gastrointestinal and Liver Disease , 12th Edition: The Gold Standard in GI Care
Serving as a definitive daily clinical reference for rare and common conditions alike. s gastrointestinal and liver disease 12th edition
continues this legacy, offering a modern, two-volume masterwork that bridges basic science with the latest clinical technologies. The text explores genetic markers, biological therapies, and
The shift toward personalized care is a major theme. The text explores genetic markers, biological therapies, and targeted treatments that allow physicians to move beyond a "one size fits all" approach to complex diseases. 3. Expanded Hepatology Coverage non-invasive fibrotic staging biomarkers
Reflecting the global nomenclature change, the textbook updates its hepatology sections from Non-Alcoholic Fatty Liver Disease (NAFLD) to . It outlines the latest metabolic diagnostic criteria, non-invasive fibrotic staging biomarkers, and emergent therapeutic targets for steatohepatitis. 3. Modernized Inflammatory Bowel Disease (IBD) Therapeutics
: Significant updates to MASLD (Metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) and new treatments for viral hepatitis and autoimmune liver diseases.
: New dedicated chapters address Gastrointestinal and Hepatic Manifestations of Coronavirus Infection (COVID-19) and Enterocolitis and Hepatitis Induced by Cancer Immunotherapy .